https://my.aptar.mobi/en-us/resources/2013-sustainability-overview always 0.9 https://my.aptar.mobi/en-us/resources/2014-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2014-sustainability-report always 0.9 https://my.aptar.mobi/en-us/resources/2014-voice-of-customer-survey-results always 0.9 https://my.aptar.mobi/en-us/resources/2015-assurance-statement-for-absolute-energy-scope-1-2-emissions-and-renewable-energy always 0.9 https://my.aptar.mobi/en-us/resources/2015-assurance-statement-for-scope-1-2-location-and-market-based-co2-emissions always 0.9 https://my.aptar.mobi/en-us/resources/2015-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2015-sustainability-report always 0.9 https://my.aptar.mobi/en-us/resources/2016-assurance-for-absolute-energy-scope-1-and-2-emissions-renewables always 0.9 https://my.aptar.mobi/en-us/resources/2016-assurance-for-scope-1-and-2-location-and-market-based-emissions always 0.9 https://my.aptar.mobi/en-us/resources/2016-corporate-sustainability-report-feedback-survey always 0.9 https://my.aptar.mobi/en-us/resources/2016-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2016-sustainability-report-and-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2017-assurance-for-absolute-energy-scope-1-and-2-emissions-renewables always 0.9 https://my.aptar.mobi/en-us/resources/2017-assurance-for-scope-1-and-2-location-and-market-based-emissions always 0.9 https://my.aptar.mobi/en-us/resources/2017-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2017-sustainability-report-and-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2018-assurance-for-absolute-energy-scope-1-and-2-emissions-renewables always 0.9 https://my.aptar.mobi/en-us/resources/2018-assurance-for-scope-1-and-2-location-and-market-based-emissions always 0.9 https://my.aptar.mobi/en-us/resources/2018-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2018-sustainability-report-and-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2019-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2019-sustainability-report-and-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2019-verification-assurance-statement-for-scope-1-2-and-3-emissions always 0.9 https://my.aptar.mobi/en-us/resources/2019-verification-letter-for-iso-14064-1-compliant-ghg-emissions always 0.9 https://my.aptar.mobi/en-us/resources/2020-cdp-climate-change-response always 0.9 https://my.aptar.mobi/en-us/resources/2020-cdp-water-security-response always 0.9 https://my.aptar.mobi/en-us/resources/2020-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2020-sustainability-report-and-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2020-task-force-on-climate-related-financial-disclosure-tcfd always 0.9 https://my.aptar.mobi/en-us/resources/2020-verification-assurance-statement-for-scope-1-2-and-3-emissions always 0.9 https://my.aptar.mobi/en-us/resources/2020-verification-letter-for-iso-14064-1-compliant-ghg-emissions always 0.9 https://my.aptar.mobi/en-us/resources/2021-cdp-climate-change-response always 0.9 https://my.aptar.mobi/en-us/resources/2021-cdp-water-security-response always 0.9 https://my.aptar.mobi/en-us/resources/2021-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2021-sustainability-accounting-standards-board-sasb-index always 0.9 https://my.aptar.mobi/en-us/resources/2021-sustainability-report-and-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2021-task-force-on-climate-related-financial-disclosure-tcfd always 0.9 https://my.aptar.mobi/en-us/resources/2021-united-nations-global-compact-report always 0.9 https://my.aptar.mobi/en-us/resources/2021-verification-assurance-statement-for-ghg-emissions-renewable-energy-waste-and-water always 0.9 https://my.aptar.mobi/en-us/resources/2021-verification-letter-for-iso-14064-1-compliant-ghg-emissions-2 always 0.9 https://my.aptar.mobi/en-us/resources/2022-carbon-transition-plan always 0.9 https://my.aptar.mobi/en-us/resources/2022-cdp-climate-change-response always 0.9 https://my.aptar.mobi/en-us/resources/2022-cdp-water-security-response always 0.9 https://my.aptar.mobi/en-us/resources/2022-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2022-sustainability-accounting-standards-board-sasb-index always 0.9 https://my.aptar.mobi/en-us/resources/2022-sustainability-report-and-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2022-task-force-on-climate-related-financial-disclosure-tcfd always 0.9 https://my.aptar.mobi/en-us/resources/2022-united-nations-global-compact-report always 0.9 https://my.aptar.mobi/en-us/resources/2022-verification-letter-for-iso-14064-1-compliant-ghg-emissions always 0.9 https://my.aptar.mobi/en-us/resources/2023-aptar-climate-transition-plan always 0.9 https://my.aptar.mobi/en-us/resources/2023-cdp-climate-change-response always 0.9 https://my.aptar.mobi/en-us/resources/2023-cdp-water-security-response always 0.9 https://my.aptar.mobi/en-us/resources/2023-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2023-sustainability-accounting-standards-board-sasb-index always 0.9 https://my.aptar.mobi/en-us/resources/2023-sustainability-report-and-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2023-task-force-on-climate-related-financial-disclosure-tcfd always 0.9 https://my.aptar.mobi/en-us/resources/2023-united-nations-global-communication-on-progress always 0.9 https://my.aptar.mobi/en-us/resources/2023-verification-statement-for-iso-14064-1-compliant-greenhouse-gas-emissions always 0.9 https://my.aptar.mobi/en-us/resources/2024-cdp-corporate-questionnaire always 0.9 https://my.aptar.mobi/en-us/resources/2024-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2024-sustainability-report-and-gri-index always 0.9 https://my.aptar.mobi/en-us/resources/2024-task-force-on-climate-related-financial-disclosure-tcfd always 0.9 https://my.aptar.mobi/en-us/resources/2024-verification-statement-for-iso-14064-1-compliant-greenhouse-gas-emissions always 0.9 https://my.aptar.mobi/en-us/resources/2025-cdp-corporate-questionnaire always 0.9 https://my.aptar.mobi/en-us/resources/2025-un-global-compact-communication-on-progress always 0.9 https://my.aptar.mobi/en-us/resources/30-years-of-ketchup-revolution always 0.9 https://my.aptar.mobi/en-us/resources/a-flavorful-squeeze always 0.9 https://my.aptar.mobi/en-us/resources/a-new-purpose-drug-repurposing always 0.9 https://my.aptar.mobi/en-us/resources/a-new-test-method-to-establish-targeted-delivery-to-the-upper-respiratory-tract always 0.9 https://my.aptar.mobi/en-us/resources/a-pharmapack-europe-2022-preview-the-future-of-medical-devices always 0.9 https://my.aptar.mobi/en-us/resources/acceptability-of-cyltezo-pen-among-patients-and-healthcare-professionals always 0.9 https://my.aptar.mobi/en-us/resources/achieving-clinical-success-with-pulmonary-delivery-for-biologics always 0.9 https://my.aptar.mobi/en-us/resources/acute-migraine-relief-nose-to-brain-delivery-with-lipid-nanoparticles always 0.9 https://my.aptar.mobi/en-us/resources/advanced-analysis-of-dry-powder-inhaler-formulations-for-bioequivalence always 0.9 https://my.aptar.mobi/en-us/resources/advanced-parenteral-closure-solutions-the-perfect-fit-towards-compliance-with-ema-gmp-annex-1-revision always 0.9 https://my.aptar.mobi/en-us/resources/advanced-stopper-solution-premiumcoat-proven-compatibility-with-current-vial-standards always 0.9 https://my.aptar.mobi/en-us/resources/advancements-in-targeted-drug-delivery-for-nasal-and-pulmonary-devices always 0.9 https://my.aptar.mobi/en-us/resources/advancing-glp-1-drug-developments-with-integrated-solutions always 0.9 https://my.aptar.mobi/en-us/resources/advancing-inhaled-nasal-drug-clinical-studies always 0.9 https://my.aptar.mobi/en-us/resources/advancing-nose-to-brain-drug-delivery-intranasal-administration-of-insulin always 0.9 https://my.aptar.mobi/en-us/resources/advancing-oindp-clinical-trials-with-speed-and-efficiency-strategies-for-success always 0.9 https://my.aptar.mobi/en-us/resources/airless-dispensing-an-opportunity-for-brands always 0.9 https://my.aptar.mobi/en-us/resources/airless-drug-delivery-widely-accepted-accessible-and-available always 0.9 https://my.aptar.mobi/en-us/resources/all-the-buzz always 0.9 https://my.aptar.mobi/en-us/resources/an-easier-way-to-get-your-vitamin-c always 0.9 https://my.aptar.mobi/en-us/resources/an-eye-on-the-future-of-preservative-free-drops always 0.9 https://my.aptar.mobi/en-us/resources/analysis-of-fluticasones-physiologic-and-pharmacokinetic-properties always 0.9 https://my.aptar.mobi/en-us/resources/analytical-services-in-the-development-of-mdis-and-dpis always 0.9 https://my.aptar.mobi/en-us/resources/applying-connectivity-to-enhance-the-training-standard-of-care-for-self-injection always 0.9 https://my.aptar.mobi/en-us/resources/approaches-to-extractables-and-leachables-in-parenteral-drugs always 0.9 https://my.aptar.mobi/en-us/resources/aptar-beauty-introduces-a-versatile-trigger-spray-portfolio-for-home-care-and-beyond always 0.9 https://my.aptar.mobi/en-us/resources/aptar-beauty-releases-covid-19-foresight-study always 0.9 https://my.aptar.mobi/en-us/resources/aptar-continues-to-provide-essential-products-during-covid-19-pandemic always 0.9 https://my.aptar.mobi/en-us/resources/aptar-pharma-discusses-intranasal-drug-delivery-with-pharmtech always 0.9 https://my.aptar.mobi/en-us/resources/aptar-pharma-etfe-film-coated-syringe-plungers-protect-sensitive-injectables always 0.9 https://my.aptar.mobi/en-us/resources/aptar-pharma-expanded-its-r-d-center-accelerating-innovation always 0.9 https://my.aptar.mobi/en-us/resources/aptar-pharma-expands-injectables-components-manufacturing-capabilities always 0.9 https://my.aptar.mobi/en-us/resources/aptar-pharma-injectable-expansion-capacity-capabilities-partnership always 0.9 https://my.aptar.mobi/en-us/resources/aptar-pharma-rfid-enabled-rigid-needle-shields-for-unit-serialization-track-and-trace always 0.9 https://my.aptar.mobi/en-us/resources/aptar-pharma-vaccine-platform-addresses-covid-19-development-life-cycle-management always 0.9 https://my.aptar.mobi/en-us/resources/aptar-pharmas-ready-to-use-program always 0.9 https://my.aptar.mobi/en-us/resources/aptar-pharmas-virtual-showcase always 0.9 https://my.aptar.mobi/en-us/resources/aptar-s-code-of-conduct-2025 always 0.9 https://my.aptar.mobi/en-us/resources/aptar-site-naming-conventions always 0.9 https://my.aptar.mobi/en-us/resources/aptars-sustainable-purchasing-charter always 0.9 https://my.aptar.mobi/en-us/resources/aptars-uds-the-trusted-platform-for-nasal-drug-delivery always 0.9 https://my.aptar.mobi/en-us/resources/assessment-of-orbital-dpi-devices-fluticasone-propionate-performance always 0.9 https://my.aptar.mobi/en-us/resources/assurance-statement-for-2014-absolute-energy-metrics always 0.9 https://my.aptar.mobi/en-us/resources/assurance-statement-for-2014-co2-emissions-scope-1-2 always 0.9 https://my.aptar.mobi/en-us/resources/beyond-probability-choosing-deterministic-methods-for-container-closure-integrity-testing always 0.9 https://my.aptar.mobi/en-us/resources/breaking-new-grounds-in-nutritional-supplements always 0.9 https://my.aptar.mobi/en-us/resources/bringing-topical-drugs-to-patients-skin-managing-the-drug-delivery-ecosystem always 0.9 https://my.aptar.mobi/en-us/resources/building-digital-solutions-to-meet-the-unique-therapeutic-needs-of-patients always 0.9 https://my.aptar.mobi/en-us/resources/case-study-bidose-nasal-spray-pump-for-depression always 0.9 https://my.aptar.mobi/en-us/resources/case-study-ophthalmic-squeeze-dispenser-and-esg always 0.9 https://my.aptar.mobi/en-us/resources/case-study-the-airless-dermal-drug-delivery-system always 0.9 https://my.aptar.mobi/en-us/resources/case-study-unidose-nasal-spray-pump-for-epilepsy always 0.9 https://my.aptar.mobi/en-us/resources/case-study-unidose-nasal-spray-pump-for-opioid-overdose always 0.9 https://my.aptar.mobi/en-us/resources/case-study-unidose-nasal-spray-pump-in-hypoglycemia always 0.9 https://my.aptar.mobi/en-us/resources/characterizing-and-controlling-foreign-particulate-matters-fpm always 0.9 https://my.aptar.mobi/en-us/resources/clean-enjoyable always 0.9 https://my.aptar.mobi/en-us/resources/climate-transition-plan-2024 always 0.9 https://my.aptar.mobi/en-us/resources/climate-transition-plan-2025 always 0.9 https://my.aptar.mobi/en-us/resources/coating-technology-combining-a-state-of-the-art-bromobutyl-formulation-with-a-proven-etfe-film-for-exceptional-chemical-performance always 0.9 https://my.aptar.mobi/en-us/resources/code-of-conduct always 0.9 https://my.aptar.mobi/en-us/resources/cold-storage-container-closure-integrity-demonstrated-performance-of-etfe-coated-components always 0.9 https://my.aptar.mobi/en-us/resources/comparison-of-pulmonary-deposition-for-single-and-multidose-dry-powder-inhalers-with-indacaterol-and-glycopyrrolate always 0.9 https://my.aptar.mobi/en-us/resources/connected-devices-digital-health-and-digital-therapeutics-where-are-we-heading-and-why always 0.9 https://my.aptar.mobi/en-us/resources/connected-health-an-effective-solution-to-improve-patient-adherence always 0.9 https://my.aptar.mobi/en-us/resources/connected-medicine-insights-from-payers-and-other-stakeholders always 0.9 https://my.aptar.mobi/en-us/resources/consistent-experience-with-dosing always 0.9 https://my.aptar.mobi/en-us/resources/consumer-driven-path-to-circularity-and-future-pharmaceutical-packaging always 0.9 https://my.aptar.mobi/en-us/resources/covid-19-drug-delivery-options-to-succeed-sooner always 0.9 https://my.aptar.mobi/en-us/resources/cyclosporine-a-micellar-nasal-spray-a-promising-antiviral-solution-against-sars-cov-2 always 0.9 https://my.aptar.mobi/en-us/resources/de-risking-combination-product-registration-for-semi-solids-with-aptar-pharma-airless-systems always 0.9 https://my.aptar.mobi/en-us/resources/decoding-article-117-of-medical-device-regulation-2017-745-as-applicable-to-integral-drug-device-combination-products always 0.9 https://my.aptar.mobi/en-us/resources/decoding-the-fdas-recent-combination-drug-product-guidance-applications-to-dpis-pmdis-and-nasal-sprays always 0.9 https://my.aptar.mobi/en-us/resources/delivering-a-material-difference-to-map-technology always 0.9 https://my.aptar.mobi/en-us/resources/delivering-nasally-administered-biologics always 0.9 https://my.aptar.mobi/en-us/resources/delivering-on-the-growing-need-for-topical-preservative-free-ophthalmic-treatments always 0.9 https://my.aptar.mobi/en-us/resources/delivering-on-the-promises-of-intranasal-vaccination always 0.9 https://my.aptar.mobi/en-us/resources/delivery-device-aerosol-deposition-characterization-of-innovative-purehale-technology-targeting-the-upper-airways always 0.9 https://my.aptar.mobi/en-us/resources/delivery-of-biologics-to-the-nasal-cavity-the-future-of-nasal-drug-delivery always 0.9 https://my.aptar.mobi/en-us/resources/derisking-the-development-of-prefilled-syringe-delivery always 0.9 https://my.aptar.mobi/en-us/resources/derisking-the-development-of-sensitive-injectables always 0.9 https://my.aptar.mobi/en-us/resources/design-meets-function always 0.9 https://my.aptar.mobi/en-us/resources/developing-a-dry-powder-formulation-for-aptar-pharma-prohaler always 0.9 https://my.aptar.mobi/en-us/resources/developing-an-in-vitro-dissolution-and-release-system-for-orally-inhaled-drug-products always 0.9 https://my.aptar.mobi/en-us/resources/developing-more-sustainable-pmdis-a-qa-on-motivation-progress-and-challenges always 0.9 https://my.aptar.mobi/en-us/resources/development-of-a-novel-nasal-spray-containing-human-recombinant-antibody-for-sars-cov-2-therapy always 0.9 https://my.aptar.mobi/en-us/resources/development-of-in-vitro-nasal-cast-imaging-techniques-to-predict-in-vivo-nasal-deposition always 0.9 https://my.aptar.mobi/en-us/resources/devices-services-for-lifecycle-management-of-crisis-medications-and-beyond always 0.9 https://my.aptar.mobi/en-us/resources/digital-health-and-oncology-innovations-in-subcutaneous-administration always 0.9 https://my.aptar.mobi/en-us/resources/dose-and-delivery-how-pmdis-are-transforming-asthma-and-copd-treatments always 0.9 https://my.aptar.mobi/en-us/resources/drug-device-digital-reimagined-healthcare always 0.9 https://my.aptar.mobi/en-us/resources/drug-repurposing-a-more-efficient-approach-to-drug-development always 0.9 https://my.aptar.mobi/en-us/resources/drug-repurposing-broadening-patient-accessibility-via-a-change-in-drug-delivery-system always 0.9 https://my.aptar.mobi/en-us/resources/elevating-medication-adherence-and-clinical-outcomes-with-connected-drug-delivery always 0.9 https://my.aptar.mobi/en-us/resources/eliminating-the-need-for-additives-in-multidose-preservative-free-eye-care-formulations always 0.9 https://my.aptar.mobi/en-us/resources/enabling-a-sustainable-future-through-packaging-innovation always 0.9 https://my.aptar.mobi/en-us/resources/end-to-end-support-at-every-stage-of-your-drug-development-journey always 0.9 https://my.aptar.mobi/en-us/resources/enhanced-injection-experience-with-pre-filled-syringe-solutions always 0.9 https://my.aptar.mobi/en-us/resources/enhancing-the-patient-experience-for-self-injection-systems always 0.9 https://my.aptar.mobi/en-us/resources/ensuring-container-integrity-at-various-temperatures always 0.9 https://my.aptar.mobi/en-us/resources/ensuring-functional-performance-and-regulatory-compliance-of-elastomer-stoppers-for-multipiercing-situations always 0.9 https://my.aptar.mobi/en-us/resources/environment-health-and-safety-policy always 0.9 https://my.aptar.mobi/en-us/resources/etfe-coated-syringe-plunger-machinability-with-vented-insertion always 0.9 https://my.aptar.mobi/en-us/resources/evaluating-the-particle-distribution-for-dry-powder-inhalers always 0.9 https://my.aptar.mobi/en-us/resources/evaluation-of-albuterol-sulfate-with-low-global-warming-potential-propellants always 0.9 https://my.aptar.mobi/en-us/resources/exploring-a-faster-more-cost-effective-alternative-to-generic-bioequivalence always 0.9 https://my.aptar.mobi/en-us/resources/exploring-a-novel-device-for-nasal-drug-delivery-to-the-olfactory-system always 0.9 https://my.aptar.mobi/en-us/resources/exploring-extractable-and-leachable-testing-strategies-for-parenterals always 0.9 https://my.aptar.mobi/en-us/resources/exploring-nasal-casts-in-nasal-drug-development always 0.9 https://my.aptar.mobi/en-us/resources/exploring-systemic-nasal-delivery-device-formulation always 0.9 https://my.aptar.mobi/en-us/resources/exploring-the-benefits-and-future-possibilities-of-nasal-drug-delivery-and-drug-repositioning always 0.9 https://my.aptar.mobi/en-us/resources/extractables-leachables-for-injectable-formulations always 0.9 https://my.aptar.mobi/en-us/resources/failure-to-start-filling-the-cracks-covid-exposed-in-patient-onboarding-support-to-enable-successful-new-therapy-initiations-in-an-uncertain-world always 0.9 https://my.aptar.mobi/en-us/resources/feasibility-of-intranasal-delivery-of-thin-film-freeze-dried-monoclonal-antibodies always 0.9 https://my.aptar.mobi/en-us/resources/feasibility-of-intranasal-delivery-of-thin-film-freeze-dried-mucoadhesive-adjuvanted-vaccine-powders always 0.9 https://my.aptar.mobi/en-us/resources/from-formulation-to-patient-intranasal-administration-of-cns-therapeutics always 0.9 https://my.aptar.mobi/en-us/resources/from-pmdi-device-to-therapeutic-effect always 0.9 https://my.aptar.mobi/en-us/resources/global-giving-policy always 0.9 https://my.aptar.mobi/en-us/resources/glp-1-drug-development-leveraging-integrated-solutions-to-improve-patient-engagement always 0.9 https://my.aptar.mobi/en-us/resources/good-medicine-solutions-for-sensitive-injectable-formulations always 0.9 https://my.aptar.mobi/en-us/resources/growing-confidence-in-airless-dispensing always 0.9 https://my.aptar.mobi/en-us/resources/helping-millions-around-the-world-breathe-easier-every-day always 0.9 https://my.aptar.mobi/en-us/resources/helping-pharma-manufacturers-meet-new-annex-1-requirements always 0.9 https://my.aptar.mobi/en-us/resources/how-aptar-beauty-leverages-in-house-ista-6-certification-testing-to-drive-faster-time-to-market-for-omnichannel-packaging-innovations always 0.9 https://my.aptar.mobi/en-us/resources/how-digital-healthcare-solutions-could-improve-patient-compliance-and-adherence always 0.9 https://my.aptar.mobi/en-us/resources/how-digital-therapeutics-add-value-to-treatments-for-complex-conditions always 0.9 https://my.aptar.mobi/en-us/resources/how-emotional-intelligence-is-driving-improvements-and-meeting-the-challenges-in-pulmonary-drug-delivery always 0.9 https://my.aptar.mobi/en-us/resources/how-evolving-patient-needs-have-fuelled-the-development-of-nasal-drug-delivery always 0.9 https://my.aptar.mobi/en-us/resources/how-high-quality-film-and-coated-elastomeric-stoppers-can-accelerate-and-derisk-your-development always 0.9 https://my.aptar.mobi/en-us/resources/how-to-rapidly-formulate-select-a-device-and-develop-a-novel-concept-for-nasal-and-pulmonary-drug-delivery always 0.9 https://my.aptar.mobi/en-us/resources/how-to-transform-beauty-packaging-from-linear-to-circular-economy always 0.9 https://my.aptar.mobi/en-us/resources/human-rights-policy always 0.9 https://my.aptar.mobi/en-us/resources/improving-intranasal-sprays-for-respiratory-viral-infections always 0.9 https://my.aptar.mobi/en-us/resources/improving-patient-adherence-and-compliance-with-innovative-digital-healthcare-solutions always 0.9 https://my.aptar.mobi/en-us/resources/in-silico-modelling-for-orally-inhaled-drug-development-oindp always 0.9 https://my.aptar.mobi/en-us/resources/in-vitro-anatomical-models-for-nasal-drug-delivery always 0.9 https://my.aptar.mobi/en-us/resources/in-vitro-and-in-vivo-assessment-of-regional-nasal-deposition-using-scintigraphy-from-a-nasal-spray-and-a-nasal-powder always 0.9 https://my.aptar.mobi/en-us/resources/inclusion-equity-belonging-policy always 0.9 https://my.aptar.mobi/en-us/resources/inclusive-packaging-design-guide always 0.9 https://my.aptar.mobi/en-us/resources/injectable-primary-packaging-complies-with-annex-1-revision always 0.9 https://my.aptar.mobi/en-us/resources/innovations-in-pulmonary-care-dpi-and-npli-lead-the-way always 0.9 https://my.aptar.mobi/en-us/resources/interview-a-structured-approach-to-the-eco-design-process always 0.9 https://my.aptar.mobi/en-us/resources/interview-with-digital-health-experts-sai-shankar-adam-shain-and-marcus-bates always 0.9 https://my.aptar.mobi/en-us/resources/interview-with-guillaume-brouet-on-aptar-pharma-services always 0.9 https://my.aptar.mobi/en-us/resources/intranasal-delivery-of-monoclonal-antibodies-via-dry-powder always 0.9 https://my.aptar.mobi/en-us/resources/intranasal-delivery-of-thin-film-freeze-dried-vaccine-powders always 0.9 https://my.aptar.mobi/en-us/resources/intranasal-immunization-promises-and-challenges always 0.9 https://my.aptar.mobi/en-us/resources/intranasal-insulin-for-alzheimer-s-advancing-brain-targeted-delivery always 0.9 https://my.aptar.mobi/en-us/resources/intranasal-vaccination-rationale-progress-and-challenges always 0.9 https://my.aptar.mobi/en-us/resources/investigating-breathable-hpv-l2-dry-powder-vaccine-using-gla-as-amphiphilic-lubricant-and-immune-adjuvant always 0.9 https://my.aptar.mobi/en-us/resources/investigating-storage-options-for-pressurized-metered-dose-inhalers always 0.9 https://my.aptar.mobi/en-us/resources/investigating-the-pharmacokinetic-properties-of-fluticasone-dry-powder-inhaler always 0.9 https://my.aptar.mobi/en-us/resources/investigating-the-propellant-pathways-leading-to-a-sustainable-future-of-mdis always 0.9 https://my.aptar.mobi/en-us/resources/investigation-of-in-vitro-dissolution-tests-for-orally-inhaled-drug-products always 0.9 https://my.aptar.mobi/en-us/resources/investigation-of-powder-blend-uniformity-and-deposition-in-a-nasal-cast-using-a-unit-dose-nasal-system always 0.9 https://my.aptar.mobi/en-us/resources/is-now-the-time-to-shake-up-the-pmdi-environment always 0.9 https://my.aptar.mobi/en-us/resources/kolibri-precision-inhalation-for-biologics-with-guided-breathing always 0.9 https://my.aptar.mobi/en-us/resources/leachables-assessment-new-pmdi-with-low-gwp-propellants always 0.9 https://my.aptar.mobi/en-us/resources/leak-detection-for-finished-sterile-containers always 0.9 https://my.aptar.mobi/en-us/resources/low-gwp-pmdi-qa-with-aptars-zen30-futurity-valve-solution always 0.9 https://my.aptar.mobi/en-us/resources/making-beauty-more-inclusive always 0.9 https://my.aptar.mobi/en-us/resources/meeting-an-unmet-need-in-pre-clinical-pulmonary-research always 0.9 https://my.aptar.mobi/en-us/resources/meeting-the-worlds-evolving-needs-for-a-more-sustainable-future-how-to-realize-a-circular-approach-to-drug-delivery-solutions always 0.9 https://my.aptar.mobi/en-us/resources/mission-possible-sustainability-in-pharmaceutical-primary-packaging always 0.9 https://my.aptar.mobi/en-us/resources/moving-toward-a-more-sustainable-future-with-pmdis always 0.9 https://my.aptar.mobi/en-us/resources/moving-towards-greater-recyclability-in-drug-delivery-sustainable-solutions-by-aptar-pharma always 0.9 https://my.aptar.mobi/en-us/resources/nanoparticle-formulation-strategies-for-intranasal-drug-delivery always 0.9 https://my.aptar.mobi/en-us/resources/nasal-casts-tools-to-enable-nasal-drug-delivery-development always 0.9 https://my.aptar.mobi/en-us/resources/nasal-delivery-of-biologics-a-whole-new-ball-game always 0.9 https://my.aptar.mobi/en-us/resources/nasal-drug-delivery-beyond-hayfever always 0.9 https://my.aptar.mobi/en-us/resources/nasal-drug-delivery-challenges-and-trends-ahead always 0.9 https://my.aptar.mobi/en-us/resources/nasal-drug-delivery-in-vitro-anatomical-models always 0.9 https://my.aptar.mobi/en-us/resources/nasal-drug-delivery-past-present-and-future-perspectives always 0.9 https://my.aptar.mobi/en-us/resources/nasal-drug-delivery-trends-challenges-and-opportunities-for-therapeutic-innovation always 0.9 https://my.aptar.mobi/en-us/resources/nasal-drug-development-trends-and-challenges-with-nasal-formulations always 0.9 https://my.aptar.mobi/en-us/resources/nasal-inhalation-testing-ipac-rs-droplet-size-analysis always 0.9 https://my.aptar.mobi/en-us/resources/nasal-spray-orientation-sumatriptan-exposure-using-pk-modelling always 0.9 https://my.aptar.mobi/en-us/resources/nasal-vaccination-promises-and-challenges always 0.9 https://my.aptar.mobi/en-us/resources/navigating-pmdi-reformulation-2-0 always 0.9 https://my.aptar.mobi/en-us/resources/navigating-the-development-for-orally-inhaled-and-nasal-drug-products always 0.9 https://my.aptar.mobi/en-us/resources/navigating-the-shift-to-more-sustainable-low-gwp-propellants-in-pmdis always 0.9 https://my.aptar.mobi/en-us/resources/new-tools-to-advance-cns-drug-delivery always 0.9 https://my.aptar.mobi/en-us/resources/north-america-food-beverage-product-catalogue always 0.9 https://my.aptar.mobi/en-us/resources/nose-to-brain-drug-delivery-a-promising-future always 0.9 https://my.aptar.mobi/en-us/resources/ocular-drug-delivery-an-interesting-past-with-a-fascinating-future always 0.9 https://my.aptar.mobi/en-us/resources/one-handed-convenience always 0.9 https://my.aptar.mobi/en-us/resources/ophthalmic-squeeze-dispenser-osd-does-one-size-fit-all always 0.9 https://my.aptar.mobi/en-us/resources/optimising-preclinical-studies-for-intranasal-and-pulmonary-programmes always 0.9 https://my.aptar.mobi/en-us/resources/optimizing-autoinjector-performance-for-drug-development always 0.9 https://my.aptar.mobi/en-us/resources/optimizing-patient-adherence-and-compliance-in-eye-care always 0.9 https://my.aptar.mobi/en-us/resources/optimizing-patient-outcomes-in-respiratory-medicine-with-digital-healthcare-devices always 0.9 https://my.aptar.mobi/en-us/resources/optimizing-preclinical-studies-for-intranasal-and-pulmonary-programs always 0.9 https://my.aptar.mobi/en-us/resources/optimizing-your-pre-clinical-discovery-in-pulmonary-nasal-drug-development always 0.9 https://my.aptar.mobi/en-us/resources/orally-inhaled-drug-products-bioequivalence-models always 0.9 https://my.aptar.mobi/en-us/resources/orbital-a-novel-dry-powder-inhaler-for-high-dose-delivery always 0.9 https://my.aptar.mobi/en-us/resources/orbital-dpi-high-payload-patient-centric-pulmonary-drug-delivery always 0.9 https://my.aptar.mobi/en-us/resources/otimizacao-de-processos-no-desenvolvimento-de-produtos-inalatorios-orais-e-nasais always 0.9 https://my.aptar.mobi/en-us/resources/overcoming-the-challenges-in-developing-an-in-vitro-dissolution-and-release-system-for-orally-inhaled-drug-products always 0.9 https://my.aptar.mobi/en-us/resources/overview-of-intranasal-drug-administration-using-multi-dose-nasal-spray-pumps always 0.9 https://my.aptar.mobi/en-us/resources/overview-of-microbial-integrity-tests-for-preservative-free-nasal-spray-pumps-and-multidose-eyedroppers always 0.9 https://my.aptar.mobi/en-us/resources/patient-focused-cancer-care-harnessing-immunotherapy always 0.9 https://my.aptar.mobi/en-us/resources/peace-of-mind-comes-with-safety always 0.9 https://my.aptar.mobi/en-us/resources/performance-of-low-gwp-propellants-in-pmdis-filling-and-dose-evaluation always 0.9 https://my.aptar.mobi/en-us/resources/pfas-program always 0.9 https://my.aptar.mobi/en-us/resources/pfs-and-autoinjector-drug-delivery-a-platform-of-primary-packaging-solutions-for-streamlined-delivery always 0.9 https://my.aptar.mobi/en-us/resources/pharma-partnering-considerations-for-injectable-device-components always 0.9 https://my.aptar.mobi/en-us/resources/pharmacokinetic-profiling-in-the-development-of-a-generic-tiotropium-dry-powder-inhaler always 0.9 https://my.aptar.mobi/en-us/resources/physiologically-based-pharmacokinetic-models-pbpk-for-oindps always 0.9 https://my.aptar.mobi/en-us/resources/plastics-treaty-position always 0.9 https://my.aptar.mobi/en-us/resources/premiumcoat-plunger-filling-lines-facilitates-sensitive-vaccines-biotech-drug-delivery always 0.9 https://my.aptar.mobi/en-us/resources/premiumcoat-solutions-helping-control-the-level-of-silicone-to-protect-sensitive-therapeutics always 0.9 https://my.aptar.mobi/en-us/resources/primary-packaging-in-the-wake-of-annex-1 always 0.9 https://my.aptar.mobi/en-us/resources/purehale-the-future-of-fine-mist-dispensers-for-upper-airway-treatments always 0.9 https://my.aptar.mobi/en-us/resources/putting-their-health-in-their-hands-enhancing-respiratory-patient-outcomes-through-digital-therapeutics always 0.9 https://my.aptar.mobi/en-us/resources/quality-safety-regulatory-compliance-for-elastomeric-closures always 0.9 https://my.aptar.mobi/en-us/resources/raising-the-bar-for-injectable-drugs-eu-gmp-annex-1-primary-packaging-considerations always 0.9 https://my.aptar.mobi/en-us/resources/reducing-pharmas-scope-3-emissions-with-low-gwp-pmdis always 0.9 https://my.aptar.mobi/en-us/resources/register-of-sustainability-certificates always 0.9 https://my.aptar.mobi/en-us/resources/replicating-the-coffee-house-experience-at-home always 0.9 https://my.aptar.mobi/en-us/resources/rethinking-oral-solid-dose-packaging always 0.9 https://my.aptar.mobi/en-us/resources/revolutionizing-cooking-in-india always 0.9 https://my.aptar.mobi/en-us/resources/round-table-evolution-of-pressurized-metered-dose-inhalers-to-cut-carbon-emissions always 0.9 https://my.aptar.mobi/en-us/resources/safe-trustworthy always 0.9 https://my.aptar.mobi/en-us/resources/sbti-certificate always 0.9 https://my.aptar.mobi/en-us/resources/small-yet-impactful-simplicycle-recyclable-valve-white-paper always 0.9 https://my.aptar.mobi/en-us/resources/sour-cream-revolution always 0.9 https://my.aptar.mobi/en-us/resources/spotlight-on-emissions-reductions-for-a-lower-co2-footprint-in-pharmaceutical-packaging always 0.9 https://my.aptar.mobi/en-us/resources/spray-dried-formulations-for-nasal-applications-challenges-and-opportunities-in-filling-and-drug-delivery always 0.9 https://my.aptar.mobi/en-us/resources/spring-2023-supplier-sustainability-engagement-playbook always 0.9 https://my.aptar.mobi/en-us/resources/step-to-success-in-nose-to-brain-drug-delivery always 0.9 https://my.aptar.mobi/en-us/resources/striving-for-a-more-circular-pharmaceutical-industry-how-aptar-pharma-can-support-your-sustainability-journey always 0.9 https://my.aptar.mobi/en-us/resources/subcutaneous-injections-new-dimension-for-an-enhanced-injection-experience always 0.9 https://my.aptar.mobi/en-us/resources/successfully-balancing-the-needs-of-the-planet-with-the-needs-of-the-patient always 0.9 https://my.aptar.mobi/en-us/resources/supplier-sustainability-engagement-playbook always 0.9 https://my.aptar.mobi/en-us/resources/supporting-improved-patient-onboarding-and-adherence-with-training-solutions always 0.9 https://my.aptar.mobi/en-us/resources/supporting-patients-and-hcps-with-new-digital-technology always 0.9 https://my.aptar.mobi/en-us/resources/sustainability-accounting-standards-board-sasb-index always 0.9 https://my.aptar.mobi/en-us/resources/sustainability-at-the-heart-of-aptar-pharmas-expansion always 0.9 https://my.aptar.mobi/en-us/resources/sustainability-measures-are-the-key-to-meeting-esg-commitments always 0.9 https://my.aptar.mobi/en-us/resources/sustainable-propellants-and-bioequivalence-innovation-in-oindps always 0.9 https://my.aptar.mobi/en-us/resources/systemic-nasal-drug-delivery-for-cns-diseases-and-beyond always 0.9 https://my.aptar.mobi/en-us/resources/take-the-next-step-on-your-brands-sustainability-journey always 0.9 https://my.aptar.mobi/en-us/resources/targeted-aerosol-delivery-to-nalt-using-bivax-intranasal-atomizer always 0.9 https://my.aptar.mobi/en-us/resources/the-art-of-ccit-deterministic-method-selection always 0.9 https://my.aptar.mobi/en-us/resources/the-control-everyone-asked-for always 0.9 https://my.aptar.mobi/en-us/resources/the-covid-19-catalyst-how-a-global-pandemic-is-accelerating-the-need-for-digital-health always 0.9 https://my.aptar.mobi/en-us/resources/the-current-state-of-play-in-connected-devices always 0.9 https://my.aptar.mobi/en-us/resources/the-go-to-drug-delivery-expert always 0.9 https://my.aptar.mobi/en-us/resources/the-importance-of-training-and-onboarding-for-intranasal-rescue-treatments always 0.9 https://my.aptar.mobi/en-us/resources/the-nasal-drug-delivery-journey-from-systemic-to-nose-to-brain always 0.9 https://my.aptar.mobi/en-us/resources/the-need-to-scale-up-digital-health-in-the-post-covid-world always 0.9 https://my.aptar.mobi/en-us/resources/the-new-imperative always 0.9 https://my.aptar.mobi/en-us/resources/the-pharmaceutical-industrys-role-in-the-global-environmental-sustainability-movement always 0.9 https://my.aptar.mobi/en-us/resources/the-potential-and-challenge-of-nasal-vaccination always 0.9 https://my.aptar.mobi/en-us/resources/the-potential-of-digital-health-in-empowering-patients-with-cancer always 0.9 https://my.aptar.mobi/en-us/resources/together-taking-innovation-sustainability-to-new-heights always 0.9 https://my.aptar.mobi/en-us/resources/topical-dermal-drug-delivery-system-innovation-and-sustainability always 0.9 https://my.aptar.mobi/en-us/resources/towards-a-more-sustainable-future-with-metered-dose-inhalers always 0.9 https://my.aptar.mobi/en-us/resources/towards-a-more-sustainable-future-with-pmdi-solutions always 0.9 https://my.aptar.mobi/en-us/resources/towards-a-new-standard-of-care-with-aptar-pharmas-digital-health always 0.9 https://my.aptar.mobi/en-us/resources/training-devices-and-patient-education-play-a-crucial-role-in-the-self-injection-drug-delivery-market always 0.9 https://my.aptar.mobi/en-us/resources/turning-categories-upside-down always 0.9 https://my.aptar.mobi/en-us/resources/under-pressure-finding-a-more-sustainable-future-for-pmdis always 0.9 https://my.aptar.mobi/en-us/resources/understanding-net-zero-and-carbon-neutrality always 0.9 https://my.aptar.mobi/en-us/resources/understanding-pbpk-modeling-in-oindps-insights-from-will-ganley always 0.9 https://my.aptar.mobi/en-us/resources/understanding-the-evolution-of-intranasal-vaccines always 0.9 https://my.aptar.mobi/en-us/resources/unlocking-therapeutic-potential-through-nasal-drug-repositioning always 0.9 https://my.aptar.mobi/en-us/resources/using-bioequivalence-and-particle-size-distribution-to-develop-oindps always 0.9 https://my.aptar.mobi/en-us/resources/using-intranasal-delivery-for-drug-repositioning-a-compelling-proposition-for-lifecycle-management always 0.9 https://my.aptar.mobi/en-us/resources/using-raman-spectroscopy-for-characterizing-nasal-suspension-drug-products always 0.9 https://my.aptar.mobi/en-us/resources/usp-382-a-shift-in-injectable-packaging-requirements always 0.9 https://my.aptar.mobi/en-us/resources/usp-382-achieving-optimal-injectable-packaging-performance always 0.9 https://my.aptar.mobi/en-us/resources/vial-stopper-compatibility-criteria-and-testing-methods always 0.9 https://my.aptar.mobi/en-us/resources/why-it-is-time-to-think-different-about-nasal-delivery-of-biologics always 0.9 https://my.aptar.mobi/en-us/resources/why-pharma-should-care-about-circular-packaging-futurity-leading-the-way always 0.9